Skip to main content
SpringerLink
Log in

An Integrated Model for Determining Causes of Poor Oral Drug Absorption

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. To develop an integrated absorption model for estimating the fraction of dose absorbed and determining the causes of poor oral drug absorption.

Methods. Both analytical and numerical methods were used to estimate the fraction of dose absorbed.

Results. An integrated absorption model was developed by considering transit flow, dissolution, and permeation processes, simultaneously. A framework was proposed to determine permeability-, dissolution-, and solubility-limited absorption. Digoxin, griseofulvin, and panadiplon were employed to illustrate the applications of the integrated model in identifying the causes of poor absorption and guiding formulation development.

Conclusions. The integrated absorption model was successfully applied to digoxin, griseofulvin, and panadiplon to estimate the fraction dose absorbed and to roughly determine the causes of poor oral drug absorption.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. L. X. Yu, J. R. Crison, E. Lipka, and G. L. Amidon. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv. Drug Del. Rev. 19:359-376 (1996).

    Google Scholar 

  2. L. X. Yu and G. L. Amidon. Characterization of small intestinal transit time distribution in humans. Int. J. Pharm. 171:157-163 (1998).

    Google Scholar 

  3. L. X. Yu and G. L. Amidon. Saturable small intestinal drug absorption in humans: modeling and explanation of the cefatrizine data. Eur. J. Pharm. Biopharm. 45:199-203, 1998.

    Google Scholar 

  4. M. Mayersohn. Principles of drug absorption. In G. S. Banker and C. T. Rhodes (eds.), Modern Pharmaceutics, 2nd ed., Marcel Dekker: New York, 1990, pp. 23-90.

    Google Scholar 

  5. R. J. Hintz and K. C. Johnson. The effect of particle size distribution on the dissolution rate and oral absorption. Int. J. Pharm. 51:9-17, 1989.

    Google Scholar 

  6. K. A. Kelly. In L. R. Johnson (Editor-in-Chief), Physiology of the Gastrointestinal Tract, Vol 1, Raven Press, New York, 1981, pp. 393-410.

    Google Scholar 

  7. J. B. Dressman and D. Fleisher. Mixing-tank model for predicting dissolution rate control of oral absorption. J. Pharm. Sci. 75:109-116 (1986).

    Google Scholar 

  8. G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413-420 (1995).

    Google Scholar 

  9. D. Z. D'Argenio and A. Schumitzky. Adapt II: Mathematical Software for Pharmacokinetic/Pharmacodynamic Systems Analysis, University of Southern California, Los Angles, 1992.

    Google Scholar 

  10. A. Astrorri, G. Bianchi, G. LaCanna, D. Assanelli, O. Visioli, and A. Marzo. Bioavailability and related heart function index of digoxin capsules and tablets in cardiac patients. J. Pharm. Sci. 68:104-106 (1979).

    Google Scholar 

  11. B. F. Johnson, J. O'Grady, and C. Bye. The influence of digoxin particle size on absorption of digoxin and the effect of porpantheline and metoclopramide. Br. J. Clin. Pharmac. 5:465-467 (1978).

    Google Scholar 

  12. A. J. Jounela, P. J. Pentikainen, and A. Sothmann. Effect of particle size on the bioavailability of digoxin. Eur. J. Clin. Pharmacol. 8:365-370 (1995).

    Google Scholar 

  13. T. R. D. Shaw and J. E. Carless. The effect of particle size on the absorption of digoxin. Eur. J. Clin. Pharmacol. 7:269-273 (1974).

    Google Scholar 

  14. D. H. Huffman and D. L. Azarnoff. Absorption of orally given digoxin preparations. JAMA. 222:957-960 (1972).

    Google Scholar 

  15. V. Manninen, A. Apajalahti, J. Melin, and M. Karesoja. Altered absorption of digoxin in patients given propantheline and metoclopramide. Lancet, 398-400 (1973).

  16. T. Gramatte. Griseofulvin absorption from different sites in the human small intestine. Biopharm. Drug Dis. 15:747-759 (1994).

    Google Scholar 

  17. W. L. Chiou and S. Riegelman. Absorption characteristics of solid dispersed and micronized griseofulvin in man. J. Pharm. Sci. 60:1376-1380 (1971).

    Google Scholar 

  18. P. Kabasakalian, M. Katz, B. Rosenkrantz, and E. Townley. Parameters affecting absorption of griseofulvin in a human study using urinary metabolite excretion data. J. Pharm. Sci. 59:595-600 (1970).

    Google Scholar 

  19. T. Nishihata, M. Ishizaka, S. Yokohama, A. C. Martino, and R. E. Gordon. Effects of particle size of bulk drug and food on the bioavailability of U-78875. Drug Dev. Ind. Pharm. 19:2679-2698 (1993).

    Google Scholar 

Download references

Author information

Author notes

  1. Lawrence X. Yu

    Present address: Food and Drug Administration, Division of Product Quality Research, 5600 Fishers Lane, Rockville, Maryland, 20857. To whom correspondence should be addressed

Authors and Affiliations

  1. Glaxo Wellcome, Inc., Five Moore Drive, Research Triangle Park, North Carolina, 27709

    Lawrence X. Yu

Authors
  1. Lawrence X. Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lawrence X. Yu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, L.X. An Integrated Model for Determining Causes of Poor Oral Drug Absorption. Pharm Res 16, 1883–1887 (1999). https://doi.org/10.1023/A:1018911728161

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018911728161

Search

Navigation